In tumour-agnostic studies, ctDNA samples are analysed without prior examination of tumour tissue, and therefore target frequently mutated genes such as KRAS, or epigenetic changes such as hypermethylation in the promotor regions of tumour suppressor genes [32]. The gene discussed is KRAS; the disease is neoplasm.